Latest News and Press Releases
Want to stay updated on the latest news?
-
– Data demonstrates Kronos Bio's approach to targeting oncogenic transcription factors and the strong relationship between IRF4 and p300 in Multiple Myeloma – – Poster presentation to take place on...
-
SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and...
-
– Data show that p300 KAT inhibitor KB-9558 was highly selective against human papillomavirus (HPV) oncoproteins E6 and E7, and therefore drove anti-tumor effects – – Poster presentation taking...